Oxford Biomedica, a contract development and manufacturing organisation specialising in cell and gene therapy, is facing a near term revenue setback even as analysts continue to forecast strong growth over the medium term. The company, traded as OTCPK:OXBD.F, has cut its guidance for the current financial year while pointing to operational delays at a key US facility as one of the causes.

Equity analysts covering the company project earnings and earnings per share growth of more than 60 per cent annually over the next three years, alongside projected annual revenue growth of 19.4 per cent. Oxford Biomedica is also expected to become profitable within that period, with analysts forecasting a return on equity of 26.2 per cent in three years. Twelve analysts currently track the company, of whom seven have submitted consensus revenue and earnings estimates.

That medium term revenue growth forecast of 19.4 per cent would place Oxford Biomedica ahead of the broader market average, which analysts put at 13.4 per cent, reflecting continued demand for bio-manufacturing capacity across the biopharmaceutical sector. However, the company's earnings growth forecast, while high in absolute terms, still trails the wider biotech sector average of 29 per cent, and its projected revenue growth of 19.4 per cent sits below the sector average of 22.8 per cent. The comparison suggests that while Oxford Biomedica's growth outlook is strong relative to the market as a whole, it is not exceptional when set against its immediate industry peers.

Despite these longer term projections, the company has revised its guidance for the 2026 financial year downward. Revenue targets, previously set at between £220 million and £240 million, have been adjusted to a range of £180 million to £200 million. The company has attributed part of this revision to short term shifts in client ordering behaviour, including deferrals of specific programmes and changes to regulatory and procurement pathways affecting some of its larger client accounts. These are the kinds of shifts common in contract manufacturing relationships, where client timelines can move for reasons unrelated to the manufacturer's own performance.

A more concrete factor behind the guidance cut relates to the company's manufacturing facility in Durham, North Carolina. Operational readiness at the site experienced a six month delay, according to the company's disclosures. That delay has since been resolved, with the facility now back on track and the first Good Manufacturing Practice batch runs under way. The extent to which this single delay accounts for the full scale of the guidance revision has not been broken down separately from the effects of client ordering changes.

Looking beyond the current financial year, Oxford Biomedica has maintained its medium term growth targets for 2027 and 2028, continuing to project annual revenue growth of between 25 and 30 per cent. This builds on what the company describes as a historical three year revenue compound annual growth rate baseline target of more than 35 per cent, a figure that suggests management retains confidence in the underlying demand for its manufacturing services even after the near term disruption.

The gap between the company's near term guidance cut and its sustained medium term ambitions raises a question that will likely occupy analysts in the coming months, namely whether the Durham delay and the shifts in client ordering represent a temporary interruption or an early signal of more persistent volatility in the CDMO's client base. With the Durham facility now producing GMP batches, the coming quarters should offer a clearer indication of whether the company's operational readiness matches the scale of growth analysts continue to forecast for 2027 and beyond.

‍